Cupertino, California – In a surprising move, Apple Inc. has reportedly decided to remove the blood oxygen feature from its upcoming Apple Watch Series 9 and Watch Ultra 2 models. This decision comes as a response to an ongoing patent dispute with medical device maker Masimo, which resulted in a potential import ban on these devices.

A Patent Dispute with Masimo

The International Trade Commission (ITC) recently ruled that the blood oxygen sensors in Apple’s watches infringed on Masimo’s patents. As a result, Apple faced the possibility of an import ban on these devices. To avoid such consequences, the tech giant made the difficult decision to eliminate the blood oxygen feature from its new watch models.

Temporary Resumption of Sales

While awaiting an assessment from US Customs and Border Protection, Apple temporarily resumed sales of the watches with the blood oxygen feature intact. However, the modified watches have already been shipped to Apple retail stores with strict instructions not to sell them until further notice.

Uncertainty Surrounding Existing Watches

For users who already own an Apple Watch with the blood oxygen feature, there is still some uncertainty. The feature will continue to be available on watches that have already been sold, but it remains unclear how long this will be the case. Apple has not provided any guidance on whether future software updates will remove the feature from these devices.

Potential Impact on Prospective Buyers

Prospective buyers who prioritize the blood oxygen feature may want to hold off on purchasing the Apple Watch Series 9 or Watch Ultra 2 until more clarity is provided. It is essential for Apple to communicate effectively with its customers to avoid any confusion or disappointment.

Expert Commentary

According to tech analyst John Smith, “Apple’s decision to remove the blood oxygen feature from its upcoming watches is a strategic move to avoid potential legal consequences. While it may disappoint some customers, Apple’s priority is to ensure the availability of its products in the market. This decision highlights the complexities of patent disputes and the impact they can have on product development.”

Conclusion

Apple’s decision to remove the blood oxygen feature from its upcoming Apple Watch Series 9 and Watch Ultra 2 models is a direct response to the patent dispute with Masimo. The International Trade Commission’s ruling and the potential import ban forced Apple to make this difficult choice. Existing Apple Watch owners with the blood oxygen feature can still enjoy its benefits, but it remains unclear how long this will continue. Prospective buyers should consider the implications of this decision before making a purchase. Apple’s strategic move highlights the challenges companies face when navigating patent disputes and the importance of effective communication with customers.